Marker Therapeutics (NASDAQ:MRKR) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Marker Therapeutics (NASDAQ:MRKR – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.02, Zacks reports.

Marker Therapeutics Stock Down 4.8%

Marker Therapeutics stock traded down $0.04 during trading on Monday, reaching $0.83. The stock had a trading volume of 135,857 shares, compared to its average volume of 151,414. Marker Therapeutics has a 52-week low of $0.82 and a 52-week high of $2.46. The business has a 50 day moving average price of $1.06 and a 200 day moving average price of $1.32. The stock has a market cap of $13.81 million, a PE ratio of -2.02 and a beta of 1.65.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Zacks Research upgraded shares of Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 15th. HC Wainwright reiterated a “buy” rating on shares of Marker Therapeutics in a report on Friday, August 21st. Finally, Weiss Ratings cut shares of Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Read Our Latest Stock Analysis on Marker Therapeutics

About Marker Therapeutics

(Get Free Report)

Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen. The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies.

Read More

Earnings History for Marker Therapeutics (NASDAQ:MRKR)

Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.